GREY:ATBPF - Post by User
Comment by
StrikingMooseon Dec 21, 2017 8:17pm
![](https://assets.stockhouse.com/kentico-cms/0338-00/images/Sprite.svg#id_Post_Views_Icon)
186 Views
Post# 27211101
RE:RE:Upgraded morningstar fair valuation $0.19
RE:RE:Upgraded morningstar fair valuation $0.19Ya buddy! Corporate update Nov 28
Development Activities for ATB-346 Progressing Well
Antibe continues to focus its development efforts on ATB-346, its lead drug that targets the global need for a safer drug for chronic pain and inflammation. The Company’s on-going Phase 2b, double-blind GI safety study for ATB-346 is progressing well and remains on schedule. As of today, 97 subjects have been enrolled (of the total 240 subjects) and the Company continues to expect a data read-out in Q1 2018 as previously disclosed.
In addition, Antibe has engaged a leading metabolism clinical research organization (“CRO”) to conduct studies to further characterize the metabolic profile of ATB-346. The Company anticipates that these metabolism studies will commence in January 2018.
Read more at https://www.stockhouse.com/news/press-releases/2017/11/28/antibe-therapeutics-reports-q2-2018-interim-financial-and-operating-results-and#4R4Fx9zsjHk59thP.99